Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar)-Reference-Cited by-同舟云学术

Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar)

Published:2020-06-10 Issue:1 Volume:16 Page:149-156
ISSN:1828-0447
Container-title:Internal and Emergency Medicine
language:en
Short-container-title:Intern Emerg Med

Author:

Vacchi Caterina,Visentini Marcella,Gragnani Laura,Fraticelli Paolo,Tavoni Antonio,Filippini Davide,Saccardo Francesco,Lauletta Gianfranco,Colantuono Stefania,Atzeni Fabiola,Pioltelli Pietro,Manfredi Andreina,Casato Milvia,Zignego Anna Linda,Monti Giuseppe,Pietrogrande Maurizio,Galli Massimo,Sebastiani Marco

Publisher

Springer Science and Business Media LLC

Subject

Emergency Medicine,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11739-020-02386-0.pdf

Reference24 articles.

1. Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, Zignego AL, Ferri C (2018) Cryoglobulinaemia. Nat Rev Dis Primers 4:11. https://doi.org/10.1038/s41572-018-0009-4

2. Silva F, Pinto C, Barbosa A, Borges T, Dias C, Almeida J (2019) New insights in cryoglobulinemic vasculitis. J Autoimmun 2:102313. https://doi.org/10.1016/j.jaut.2019.102313

3. Galli M, Monti G, Marson P, Scaini P, Pietrogrande M, Candela M, Castelnovo L, Faggioli P, Novati P, Zani R, Mascia MT, Saccardo F, Mazzaro C, Sarzi-Puttini P, Sebastiani M, Quartuccio L, De Vita S (2019) Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. Autoimmun Rev 18:778–785. https://doi.org/10.1016/j.autrev.2019.06.008

4. Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, Sansonno S, Russi S, Mariggiò MA, Chironna M, Sansonno D (2010) Pegylated interferon-alpha ribavirin rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 116:343–353. https://doi.org/10.1182/blood-2009-10-245878

5. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G (2012) A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 64:843–853. https://doi.org/10.1002/art.34331

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AB0775 EFFECTIVENESS AND SAFETY OF NON-MEDICAL SWITCH FROM RITUXIMAB ORIGINATOR TO AND AMONG BIOSIMILARS IN SMALL VESSEL VASCULITIDES PATIENTS: REAL WORLD DATA FROM A RETROSPECTIVE MONOCENTRIC STUDY;Scientific Abstracts;2023-05-30

2. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC);Clinical Rheumatology;2022-09-28

3. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements;Clinical and Experimental Medicine;2022-03-28

4. A Developer’s Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10;Clinical Drug Investigation;2022-03-24

5. Impact of direct acting antivirals on hepatitis C virus-related cryoglobulinemic syndrome;Minerva Gastroenterology;2021-10